Showing 1651-1660 of 5853 results for "".
Clinical Data on Switching to Upadacitinib
https://practicaldermatology.com/series/updates-atopic-dermatitis/clinical-data-on-switching-to-upadacitinib/36534/Clinical investigator Christopher Bunick, MD, PhD, discusses results from the LEVEL UP trial among patients who switched from dupilumab to upadacitinib for atopic dermatitis.The Biosimilar Revolution: A Look at the Potential Impact
https://practicaldermatology.com/issues/april-2025/the-biosimilar-revolution-a-look-at-the-potential-impact/35596/With many biosimilars expected to gain regulatory approval in coming months and years, Practical Dermatology interviewed Collin Blattner, DO, FAAD—an editorial board member and double-board–certified dermatologist who owns Clearchoice Dermatology, which has 12 locations in Oregon and Washington—abouSkin Coverage as a Medical Benefit
https://practicaldermatology.com/series/c-suite-chats/skin-coverage-as-a-medical-benefit/35559/Mike Jafar, Founder and CEO of Joya Health, talks about the importance of having skin coverage as a medical benefit, trends in dermatology, and the driver behind the rising rates of melanoma.Addressing Equity Gaps in Psoriasis Research
https://practicaldermatology.com/series/c-suite-chats/addressing-equity-gaps-in-psoriasis-research/33151/LaShell Robinson, Head, Global Feasibility and Trial Equity for Takeda, discusses the disproportionate underrepresentation of certain racial and ethnic groups in clinical trials, especially for psoriasis, and how Takeda is seeking to close those gaps in recent Phase 3 trials.Nemluvio Gains Two Major Indications in Europe
https://practicaldermatology.com/series/dermwire-tv/nemluvio-gains-two-major-indications-in-europe/32982/In this week's DermwireTV, Nemluvio is approved for two new indications in Europe; new patient-centric guidelines for generalized pustular psoriasis (GPP) management are unveiled; and in our C-Suite Chats feature, we are joined by the Co-Founder and CEO of Veradermics.'Combination Is Back,' Doctor Declares at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/combination-is-back-doctor-declares-at-maui-derm/32918/One of the most important studies of the past few years for dermatologists involved patients with ulcerative colitis, according to Arthur Kavanaugh, MD.Pediatric, Acne, and AD Sessions: Dr. Eichenfield
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/pediatric-acne-and-ad-sessions-dr-eichenfield/32684/Lawrence Eichenfield, MD, discusses his presentations from Maui Derm 2025, which included "Pediatric Dermatology 2025," "Update 2025: Acne and Rosacea," and "Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2025." Highlights include the importance of recognizing severe and rapidMaking Hair Care Safer for Skin
https://practicaldermatology.com/series/c-suite-chats/making-hair-care-safer-for-skin/32711/Iris Rubin, Founder and Chief Medical Officer of SEEN, discusses how hair care products can cause a variety of skin issues, and the process in which she developed SEEN hair care.Epidermal Inclusion Cysts: Dr. Goldman
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/epidermal-inclusion-cysts-dr-goldman/32687/Mitchel Goldman, MD, who took part in the "Neuromodulator and Dermal Filler" panel at Maui Derm 2025, talks about a new treatment for epidermal inclusion cysts, involving sclerotherapy medication.Combination Treatment: Dr. Shamban
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/combination-treatment-dr-shamban/32685/Ava Shamban, MD, talks about the combination treatments—such as energy-based devices, peels, and laser-assisted drug delivery—that she covered in "What's My Treatment? How to Combine Dermal Filler, Neuromodulators, Laser/Light/RF Devices/Microneedling and Cosmeceuticals Symposium" at Maui Derm 2025.